METTL3 suppresses pancreatic ductal adenocarcinoma progression through activating endogenous dsRNA-induced anti-tumor immunity
Cellular Oncology · 2023-10 · 46 (5) · 1529-1541
DOI: 10.1007/s13402-023-00829-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Oncology, online erschienen am 13.05.2023. Verfasst von Lili Zhu und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai Immune Therapy Institute, Ren Ji Hospital, School of Medicin…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Postdoctoral Program for Innovative Talents, Natural Science Foundation of Shanghai, National Natural Science Foundation of China.
Abstract (Originalsprache)
PURPOSE: Although immunotherapy improves clinical outcomes in several types of malignancies, as an immunologically 'cold' tumor, pancreatic ductal adenocarcinoma (PDAC) is arrantly resistant to immunotherapy. However, the role of N6-methyladenosine (m6A) modification in the immune microenvironment of PDAC is still poorly understood. METHODS: The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets were used to identify differentially expressed m6A related enzymes. The biological role and mechanism of METTL3 in PDAC growth and metastasis were determined in vitro and in vivo. RNA-sequencing and bioinformatics analysis were used to identify signaling pathways involved in METTL3. Western blot, m6A dot blot assays, co-immunoprecipitation, immunofluorescence, and flow cytometry were used to explore the molecular mechanism. RESULTS: Here, we demonstrate that METTL3, the key regulator of m6A modification, is downregulated in PDAC, and negatively correlates with PDAC malignant features. Elevated METTL3 suppresses PDAC growth and overcomes resistance to immune checkpoint blockade. Mechanistically, METTL3 promotes the accumulation of endogenous double-stranded RNA (dsRNA) through protecting m6A-transcripts from further Adenosine-to-inosine (A-to-I) editing. The dsRNA stress activates RIG-I-like receptors (RLRs) to enhance anti-tumor immunity, finally suppressing PDAC progression. CONCLUSION: Our findings indicate that tumor cell-intrinsic m6A modification participates in the regulation of tumor immune landscape. Adjusting the m6A level may be an effective strategy to overcome the resistance to immunotherapy and increase responsiveness to immunotherapy in PDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai Immune Therapy Institute, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
- State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
- Institute of Oncology, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
- State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. shjiang@shsci.org.
- State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. xlzhang@shsci.org.
Förderung
- National Postdoctoral Program for Innovative Talents
- Natural Science Foundation of Shanghai
- National Natural Science Foundation of China
Zitieren
APA
Zhu, L., Li, B., Li, R., Hu, L., Zhang, Y., Zhang, Z., Jiang, S., & Zhang, X. (2023). METTL3 suppresses pancreatic ductal adenocarcinoma progression through activating endogenous dsRNA-induced anti-tumor immunity. Cellular Oncology, 46(5), 1529-1541. https://doi.org/10.1007/s13402-023-00829-2
Vancouver
Zhu L, Li B, Li R, Hu L, Zhang Y, Zhang Z, et al. METTL3 suppresses pancreatic ductal adenocarcinoma progression through activating endogenous dsRNA-induced anti-tumor immunity. Cellular Oncology. 2023;46(5):1529-1541. doi:10.1007/s13402-023-00829-2
BibTeX
@article{Zhu2023,
author = {Zhu, Lili and Li, Botai and Li, Rongkun and Hu, Lipeng and Zhang, Yanli and Zhang, Zhigang and Jiang, Shuheng and Zhang, Xueli},
title = {METTL3 suppresses pancreatic ductal adenocarcinoma progression through activating endogenous dsRNA-induced anti-tumor immunity},
journal = {Cellular Oncology},
year = {2023},
volume = {46},
number = {5},
pages = {1529--1541},
doi = {10.1007/s13402-023-00829-2}
}
EUVIMED